Mass Accumulation Rate (MAR) as a Predictive Biomarker for Treatment Selection in Multiple Myeloma Verified

What's the purpose of this trial?

The goal of this trial is to see whether a test based on a new technology which assesses tumor cell mass accumulation rate (MAR) can help to predict how patients with relapsed/refractory disease will respond to multiple myeloma treatments.

This trial is open but patient recruitment is temporarily on hold.


What will happen during the trial?

Researchers are asking patients who participate in this clinical trial to provide an approximately 10mL (2 teaspoons) bone marrow sample. This sample will be collected at a time when a bone marrow biopsy is already being performed as part of your standard of care treatment and will not require an additional procedure. This study has two groups, also called cohorts. Each cohort will provide the same volume of a one-time bone marrow sample.

  • Vanguard Cohort – This group of patients should not have received prior treatment for their myeloma.
  • Relapsed/Refractory Cohort – This group of patients should have relapsed/refractory disease and be within 4 weeks of starting their next line of therapy.

Researchers are also requesting access to your medical information and myeloma treatment history. This data will be de-identified, and securely stored.

If you agree to take part in this study, there will be no direct medical benefit or additional costs to you.

You and your physician will not be informed of the results of the tests on your tumor cells at the time your physician is deciding on your treatment as the accuracy of this test is not yet proven. Proving the value of this this test is the purpose of this study. The testingprocedure is not a treatment. There is no benefit to participating in this part of the study except for the satisfaction of contributing to scientific knowledge. We hope the information learned from this study will benefit other people with multiple myeloma in the future.


Additional Trial Information

Observational Trial

Enrollment: 130 patients (estimated)

View More

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required. Create your account or call us today for help (888) 828-2206.

  • Depending on the cohort, eligible patients must either:
    • Be treatment naïve, which means no prior treatment for their multiple myeloma
    • Be relapsed/refractory, and within four weeks of beginning their second (or greater) line of therapy.
  • Patient’s oncologist must be planning on prescribing one of the following therapeutic courses as the next line of treatment:
    • Revlimid, Velcade and dexamethasone (RVd)
    • Velcade, Cytoxan and dexamethasone (VCd)
    • Kyprolis, Revlimid and dexamethasone (KRd)
    • Pomalyst, Velcade and dexamethasone (PVd)
    • Kyprolis, Pomalyst and dexamethasone (KPd)
    • Revlimid and dexamethasone (Rd)
    • Pomalyst and dexamethasone (Pd)
    • Kyprolis and dexamethasone (Kd)
    • Ixazomib, Pomalyst and dexamethasone (IPd)
    • Ixazomib, Revlimid and dexamethasone (IRd)
    • Revlimid, Cytoxan and dexamethasone (RCd)
    • Pomalyst, Cytoxan and dexamethasone (PCd)
    • Venetoclax
    • Velcade, dexamethasone and venetoclax (Vd + venetoclax)
    • Kyprolis, dexamethasone and venetoclax (Kd + venetoclax)
    • Selinexor and dexamethasone (Sd)
  • Patients must not have had prior CAR-T therapy exposure.
  • Patients must not have had a prior allogeneic transplant.
  • Patients for whom daratumumab or elotuzumab is a component of their next line of therapy may not join this trial.
View Additional Criteria

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

California

City of Hope Comprehensive Cancer Center Beckman Research Institute

Duarte, CA

Recruitment on Hold

Georgia

Winship Cancer Institute of Emory University

Atlanta, GA

Recruitment on Hold

Massachusetts

Dana-Farber Cancer Institute

Boston, MA

Recruitment on Hold

Massachusetts General Hospital

Boston, MA

Recruitment on Hold

Beth Israel Deaconess Medical Center

Boston, MA

Upcoming Center

New York

Mount Sinai Hospital Tisch Cancer Institute

New York, NY

Recruitment on Hold

Weill Cornell Medicine

New York, NY

Recruitment on Hold

Trial Links

Read the latest news and updates on this trial.

Weighing Cancer Cells for Personalized Myeloma Therapy with Clifford Reid, PhD, Travera

October 23, 2019

Can you tell how well a myeloma treatment might work on your personal tumor by weighing the cancer cells? Clifford Reid, PhD and CEO of Travera shares a new approach to “personalized medicine” in multiple myeloma.

Read more
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with Travera LLC to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors